Skip to main content

Mechanistic basis of cancer immunotherapy

Wednesday, April 18, 2018 - 3:00pm to 4:00pm


Ira Mellman, Ph.D.
Vice President, Cancer Immunology
Genentech, Inc.


My group’s long interest in understanding the cellular mechanisms of the immune response has increasingly focused on the problem of cancer immunology and immunotherapy. We have now established an entire department devoted to this effort, and postdocs in my group seek to understand how checkpoint inhibitors (eg anti-PD-L1), vaccines, immune agonists and their combinations work to produce durable anti-cancer responses.

The page was last updated on Tuesday, September 26, 2017 - 2:53pm